What is the current stock price of Ovid Therapeutics Inc. (OVID)?

As of the latest market data, Ovid Therapeutics Inc. (OVID) is trading at $2.54. The stock has seen a gain of 3.67% today.

Does Ovid Therapeutics Inc. (OVID) pay a dividend?

Based on current data, Ovid Therapeutics Inc. does not have a confirmed active dividend policy.

What is the market cap of Ovid Therapeutics Inc.?

The current market capitalization of Ovid Therapeutics Inc. (OVID) is approximately unavailable.

OVID

Ovid Therapeutics Inc.·Healthcare

2.54

3.673%(+0.09)

Close Price

2.71

6.693%(+0.17)

After Hours

Last Updated: — ET

52W L: $0.2752W H: $3.10

OVID NEWS

globenewswire.com

May 12

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studies Announced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), conditions for which GABA-aminotransferase (GABA-AT) inhibition is a validated mechanism Strengthened balance sheet, raising $60.0 million of gross proceeds in March 2026 PIPE financing with participation from leading healthcare investors Received $53.9 million in gross proceeds upon full exercise of Series A warrants in connection with October 2025 PIPE financing Cash, cash equivalents and marketable securities were $165.6 million as of March 31, 2026, which does not include $27.3 million in proceeds received in April 2026 from exercise of Series A warrants NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the first quarter ended March 31, 2026. “Our first quarter reflected focused execution and continued progress across our pipeline of potentially transformative small molecule medicines for intractable brain conditions,” stated Meg Alexander, President and Chief Executive Officer.

proactiveinvestors.com

Apr 27

AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical research. The clinical-stage biotechnology company said the award highlights a multiyear partnership aimed at incorporating the lived experiences of clinical trial participants into the development of mental health treatments.

seekingalpha.com

Apr 14

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

globenewswire.com

Apr 8

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously. During the event independent expert clinicians and translational experts as well as Ovid's President and Chief Executive Officer Meg Alexander, will discuss the Company's proprietary portfolio of potential first-in-class direct activators of KCC2, including pharmacodynamic data, translational and clinical development strategy, and the potential market opportunity.

defenseworld.net

Mar 26

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to

seekingalpha.com

Mar 20

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, extending the cash runway into 2029, but a $385.7M modeled funding gap implies 11% annual dilution over six years.

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-05-05

Beta

0.19

Websitewww.ovidrx.com↗